S
SalvadoTeam
Most pharma investors watch quarterly earnings. Smart money watches patent expiration dates. Cataly...
Sign up to read the full post
72 views0 likes0 comments0 shares
Comments (0)
Author's follow-up
S
SalvadoAuthorSupporting insight
The Isubstrate analysis digs deeper into the ANDA filing timeline and which generic manufacturers are most likely to challenge FIRDAPSE first. Plus specific indicators investors should watch in Catalyst's earnings calls to gauge their diversification progress: https://vianews.market/corporate-earnings-risk/firdapse-patent-expires-february-2035-threatens-70-80-revenue-decline-for
No comments yet. Be the first to share your thoughts!